Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Proqr Therapeutics Ii B V operates a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 2 pending office actions. These actions are distributed across 2 distinct examiners and 1 distinct art unit. This distribution shows that while the company's patenting activity involves different personnel, it is concentrated within a single technical division of the patent office. The presence of 1 distinct art unit suggests a consistent technical focus for the current filings. This concentration allows the company to maintain a unified technical narrative across its active matters in biotechnology.
The busiest examiner for Proqr Therapeutics Ii B V is CHONG, KIMBERLY, who is responsible for 1 pending office action. This examiner handles 1 busiest examiner pending case. The remaining pending action is handled by another of the 2 distinct examiners. Because all activity is within 1 distinct art unit, the company must manage different examiner styles but within the same administrative group. The prosecution strategy for Proqr Therapeutics Ii B V involves navigating multiple examiners simultaneously. This diversity in examiners requires a varied approach to legal arguments even though the technical group remains the same. The outcome of the portfolio is not dependent on a single individual's review, providing some balance in the prosecution process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, KIMBERLY | 1 | 72.4% | +13.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18477366 | NUCLEIC ACID MOLECULES FOR PSEUDOURIDYLATION | CHONG, KIMBERLY | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18477366 | NUCLEIC ACID MOLECULES FOR PSEUDOURIDYLATION | CHONG, KIMBERLY | — | §112DP | Non-Final OA | — | Pending | Sep 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial